John Cunningham

2Flo Ventures thesis

Vivacelle Bio Vivacelle Bio leverages phospholipid nanoparticles treating relative (nitric oxide induced) and absolute hypovolemia due to septic or hemorrhagic shock. Temprian Therapeutics A biotech company focused on developing a safe and effective treatment for the skin depigmentation disease, Vitiligo. Delphian Therapeutics Delphian Therapeutics is a pioneer in FDA-approved, cannabinoid-based pain relief for hard-to-treat musculoskeletal and neurological conditions. Pain is commonly undertreated in patients of color and is shown to exacerbate adverse health outcomes. ResQ Pharma ResQ Pharma

Sector and stage focus

• Series A: Health IT, Health & Hospital Services, Digital Health
• Seed: Health IT, Digital Health, Health & Hospital Services

Is John Cunningham a fit for your round?

Upload your pitch deck and see whether John Cunningham appears in your top 20 matches.